US FDA’s Stein ‘Excited’ About Real-World Evidence, Rare Disease Endpoint Pilot Programs
Executive Summary
Head of Office of New Drugs highlights programs being established under PDUFA VII that could help overcome obstacles in drug development.
You may also be interested in...
Real-World Data: FDA Urged To Distinguish Between Electronic Health Records And Medical Claims
Comments on September draft guidance seek more attention to differences between the two types of data sources; pharma firms said they may not always have access to all the information the US FDA wants to see about a particular data source, and they seek additional flexibility on validation.
Califf Outlines Clinical Trial Reform Message, Which Could Travel With Him To Commissioner’s Office
US FDA commissioner-nominee Califf calls for streamlining clinical trial bureaucracy, as well as open access to clinical data.
Califf Likely To Find Many Familiar Problems Upon Return To US FDA Helm
President Biden’s pick for FDA commissioner should remember many of the hot-button issues that he would face upon confirmation, such as drug pricing and approval standards.